Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tibor Bakacs

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Seminars in Cancer Biology|February 14, 2021
Tackling cancer cell dormancy: Insights from immune models, and transplantationAlexandre Corthay, Tibor Bakacs, Govindarajan Thangavelu, et al.
Pharmacological Research|April 17, 2012
Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy)Tibor Bakacs, Jitendra N Mehrishi, Miklós Szabó, et al.
Cureus|May 19, 2021
Complete Remission of Vocal Cord Cancer Treated With Low-Dose Ipilimumab Plus Nivolumab Combined With Interleukin-2 and HyperthermiaRalf Kleef, Viktor Bacher, Robert Nagy, et al.
Cureus|April 4, 2022
Sequential Combination of a Strong Interferon Inducer Viral Vector With Low Doses of Nivolumab Plus Ipilimumab Could Provide Functional Cure in Chronic Hepatitis B Virus infections: Technical Report Proposing a New ModalityTibor Bakacs, Rifaat Safadi, László G Puskás, et al.
Cancer Immunology, Immunotherapy : CII|March 11, 2020
Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapiesCsaba Kerepesi, Tibor Bakacs, Ralph W Moss, et al.
Integrative Cancer Therapies|September 9, 2018
Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2Ralf Kleef, Ralph Moss, A Marcell Szasz, et al.
Infectious Disorders Drug Targets|April 20, 2022
A Clinically Validated, Broadly Active, Oral Viral Superinfection Therapy Could Mitigate Symptoms in Early-stage COVID-19 PatientsTibor Bakacs, Volker Sandig, Shimon Slavin, et al.
Scandinavian Journal of Immunology|October 8, 2019
Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancerTibor Bakacs, Ralph W Moss, Ralf Kleef, et al.
JCO Precision Oncology|February 8, 2024
Association of Baseline Tumor-Specific Neoantigens and CD8<sup>+</sup> T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint InhibitorsCsaba Kerepesi, Hassan Mohammed Abushukair, Biagio Ricciuti, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Seminars in Cancer Biology|February 14, 2021
Tackling cancer cell dormancy: Insights from immune models, and transplantationAlexandre Corthay, Tibor Bakacs, Govindarajan Thangavelu, et al.
Pharmacological Research|April 17, 2012
Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy)Tibor Bakacs, Jitendra N Mehrishi, Miklós Szabó, et al.
Cureus|May 19, 2021
Complete Remission of Vocal Cord Cancer Treated With Low-Dose Ipilimumab Plus Nivolumab Combined With Interleukin-2 and HyperthermiaRalf Kleef, Viktor Bacher, Robert Nagy, et al.
Cureus|April 4, 2022
Sequential Combination of a Strong Interferon Inducer Viral Vector With Low Doses of Nivolumab Plus Ipilimumab Could Provide Functional Cure in Chronic Hepatitis B Virus infections: Technical Report Proposing a New ModalityTibor Bakacs, Rifaat Safadi, László G Puskás, et al.
Cancer Immunology, Immunotherapy : CII|March 11, 2020
Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapiesCsaba Kerepesi, Tibor Bakacs, Ralph W Moss, et al.
Integrative Cancer Therapies|September 9, 2018
Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2Ralf Kleef, Ralph Moss, A Marcell Szasz, et al.
Infectious Disorders Drug Targets|April 20, 2022
A Clinically Validated, Broadly Active, Oral Viral Superinfection Therapy Could Mitigate Symptoms in Early-stage COVID-19 PatientsTibor Bakacs, Volker Sandig, Shimon Slavin, et al.
Scandinavian Journal of Immunology|October 8, 2019
Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancerTibor Bakacs, Ralph W Moss, Ralf Kleef, et al.
JCO Precision Oncology|February 8, 2024
Association of Baseline Tumor-Specific Neoantigens and CD8<sup>+</sup> T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint InhibitorsCsaba Kerepesi, Hassan Mohammed Abushukair, Biagio Ricciuti, et al.
Pageof 2